Quality investing has a clear philosophy: identify companies with sustainable competitive advantages, consistent profitability, solid financial health, and a proven ability to grow while generating strong returns on capital. The strategy is less about hunting for bargains and more about paying a fair price for businesses that can compound value over the long haul. Using a structured screen based on quality principles, STERIS PLC (NYSE:STE) emerges as a strong candidate. The screen focuses on quantifiable metrics—historical revenue and profit growth, improving margins, high returns on invested capital (ROIC), manageable debt, and the conversion of earnings into free cash flow—to filter for companies that fit the quality profile.
[stock-image]
Recent Performance and Growth Metrics
STERIS has demonstrated a solid track record of expansion that aligns with quality criteria. The company’s revenue compound annual growth rate (CAGR) over the past five years stands at 6.33%, comfortably exceeding the screen’s minimum 5% threshold. More notably, EBIT growth over the same period reaches 15.31%, which is significantly higher than revenue growth. This is a key quality indicator: it suggests that STERIS is not just getting bigger, but more efficient—enjoying economies of scale or pricing power that allows operating profits to outpace top-line expansion. Future revenue growth is also projected above 5% over the next three years, indicating the momentum is expected to continue.
Profitability and Returns on Capital
At the heart of quality investing is the return a company earns on the capital it deploys. The screen requires a ROIC (excluding cash, goodwill, and intangibles) above 15%. STERIS delivers a strong 25.28% on this measure. This high and improving return signals that management is adept at allocating capital into profitable projects, a hallmark of a business with a durable competitive advantage. The company’s operating margin of 18.73% and profit margin of 13.18% both rank among the top decile of its industry peers in the Health Care Equipment & Supplies sector, further confirming its profitability edge. The underlying profitability trends are positive as well, with operating margin, profit margin, and ROIC all showing growth over the past five years.
Financial Health and Cash Conversion
Quality companies should not be overly burdened by debt. The screen limits debt to free cash flow (FCF) at a ratio below 5 times. STERIS’s Debt/FCF ratio is an excellent 1.99, indicating it could theoretically repay all outstanding debt in less than two years of free cash flow. This strong solvency is echoed by an Altman-Z score of 4.98, well above the danger zone, and a manageable debt-to-equity ratio of 0.25.
Cash conversion quality is another crucial filter. The screen looks for a five-year average profit quality—free cash flow as a percentage of net income—above 75%. STERIS scores an outstanding 188.97%, meaning it generates significantly more free cash flow than its reported net income. This points to a conservative accounting approach and a business model that turns earnings into real, usable cash efficiently. The combination of strong cash generation, low leverage, and high capital returns creates a solid foundation for long-term compounding.
Valuation Considerations
While quality screens do not demand deep value, valuation cannot be ignored. STERIS trades at a P/E ratio of 21.24, which is above the broad market but actually cheaper than the majority of its industry peers. The forward P/E of 19.16, combined with expected EPS growth of 8.80% annually, results in a PEG ratio that suggests the growth is priced at a reasonable premium—not excessive for a company with this profitability profile. The elevated free cash flow yield also provides a margin of safety relative to many competitors.
Based on these fundamentals, STERIS earns a high overall fundamental rating of 7 out of 10. The strength lies particularly in profitability (score of 8) and financial health (score of 8), while valuation and growth are rated as moderate. The full detailed analysis can be accessed in the fundamental report on Chartmill.
Summary
STERIS PLC exhibits the core traits that quality investors seek: sustained top- and bottom-line growth, improving operational efficiency, a high and increasing return on invested capital, low debt relative to cash flow, and exceptional conversion of earnings into free cash. It is a well-capitalized business operating in a critical and recurring-demand sector—healthcare sterilization and life sciences—which adds an element of economic resilience. For those applying the principles of quality investing, the combination of these measurable characteristics makes STERIS a stock worth examining further.
More stocks that pass similar quality screens can be explored via the Chartmill stock screener, where additional filtering options are available.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions. Past performance is not indicative of future results.
Read full article here »
View the Zacks #1 Rank List
STERIS PLC (NYSE:STE): A Quality Investing Standout
Quality investing has a clear philosophy: identify companies with sustainable competitive advantages, consistent profitability, solid financial health, and a proven ability to grow while generating strong returns on capital. The strategy is less about hunting for bargains and more about paying a fair price for businesses that can compound value over the long haul. Using a structured screen based on quality principles, STERIS PLC (NYSE:STE) emerges as a strong candidate. The screen focuses on quantifiable metrics—historical revenue and profit growth, improving margins, high returns on invested capital (ROIC), manageable debt, and the conversion of earnings into free cash flow—to filter for companies that fit the quality profile.
[stock-image]
Recent Performance and Growth Metrics
STERIS has demonstrated a solid track record of expansion that aligns with quality criteria. The company’s revenue compound annual growth rate (CAGR) over the past five years stands at 6.33%, comfortably exceeding the screen’s minimum 5% threshold. More notably, EBIT growth over the same period reaches 15.31%, which is significantly higher than revenue growth. This is a key quality indicator: it suggests that STERIS is not just getting bigger, but more efficient—enjoying economies of scale or pricing power that allows operating profits to outpace top-line expansion. Future revenue growth is also projected above 5% over the next three years, indicating the momentum is expected to continue.
Profitability and Returns on Capital
At the heart of quality investing is the return a company earns on the capital it deploys. The screen requires a ROIC (excluding cash, goodwill, and intangibles) above 15%. STERIS delivers a strong 25.28% on this measure. This high and improving return signals that management is adept at allocating capital into profitable projects, a hallmark of a business with a durable competitive advantage. The company’s operating margin of 18.73% and profit margin of 13.18% both rank among the top decile of its industry peers in the Health Care Equipment & Supplies sector, further confirming its profitability edge. The underlying profitability trends are positive as well, with operating margin, profit margin, and ROIC all showing growth over the past five years.
Financial Health and Cash Conversion
Quality companies should not be overly burdened by debt. The screen limits debt to free cash flow (FCF) at a ratio below 5 times. STERIS’s Debt/FCF ratio is an excellent 1.99, indicating it could theoretically repay all outstanding debt in less than two years of free cash flow. This strong solvency is echoed by an Altman-Z score of 4.98, well above the danger zone, and a manageable debt-to-equity ratio of 0.25.
Cash conversion quality is another crucial filter. The screen looks for a five-year average profit quality—free cash flow as a percentage of net income—above 75%. STERIS scores an outstanding 188.97%, meaning it generates significantly more free cash flow than its reported net income. This points to a conservative accounting approach and a business model that turns earnings into real, usable cash efficiently. The combination of strong cash generation, low leverage, and high capital returns creates a solid foundation for long-term compounding.
Valuation Considerations
While quality screens do not demand deep value, valuation cannot be ignored. STERIS trades at a P/E ratio of 21.24, which is above the broad market but actually cheaper than the majority of its industry peers. The forward P/E of 19.16, combined with expected EPS growth of 8.80% annually, results in a PEG ratio that suggests the growth is priced at a reasonable premium—not excessive for a company with this profitability profile. The elevated free cash flow yield also provides a margin of safety relative to many competitors.
Based on these fundamentals, STERIS earns a high overall fundamental rating of 7 out of 10. The strength lies particularly in profitability (score of 8) and financial health (score of 8), while valuation and growth are rated as moderate. The full detailed analysis can be accessed in the fundamental report on Chartmill.
Summary
STERIS PLC exhibits the core traits that quality investors seek: sustained top- and bottom-line growth, improving operational efficiency, a high and increasing return on invested capital, low debt relative to cash flow, and exceptional conversion of earnings into free cash. It is a well-capitalized business operating in a critical and recurring-demand sector—healthcare sterilization and life sciences—which adds an element of economic resilience. For those applying the principles of quality investing, the combination of these measurable characteristics makes STERIS a stock worth examining further.
More stocks that pass similar quality screens can be explored via the Chartmill stock screener, where additional filtering options are available.
Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. Always conduct your own research and consider your financial situation before making investment decisions. Past performance is not indicative of future results.
Read full article here »